Pyrimethamine
Dihydrofolate Reductase Inhibitor Antimalarial — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
Also known as: chloridin, chloridine, diaminopyritamin, pirimecidan, pirimetamin, pyrimethamin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Pyrimethamine is an ofp drug in the Dihydrofolate Reductase Inhibitor Antimalarial class catalogued in DrugCentral. It was first approved by the FDA in 1953. Its mechanism of action is classified as Dihydrofolate Reductase Inhibitors. DrugCentral lists 23 molecular targets, including Bifunctional dihydrofolate reductase-thymidylate synthase, Bifunctional dihydrofolate reductase-thymidylate synthase and dfrA17. Recorded indications include Chloroquine Resistant Plasmodium Falciparum Malaria, Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Encephalitis due to Toxoplasmosis and Malaria.
- Approval status: ofp (first approved 1953 by the FDA).
- Drug class: Dihydrofolate Reductase Inhibitor Antimalarial.
- Mechanism of action: Dihydrofolate Reductase Inhibitors.
- Molecular targets: Bifunctional dihydrofolate reductase-thymidylate synthase, Bifunctional dihydrofolate reductase-thymidylate synthase, dfrA17 and folA (23 listed in DrugCentral).
- Indications: Chloroquine Resistant Plasmodium Falciparum Malaria, Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Encephalitis due to Toxoplasmosis, Malaria and Toxoplasmosis and others.
- ATC code: P01BD01 (Diaminopyrimidines).
- Molecular formula: C12H13ClN4; molecular weight 248.71 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (6)
- Chloroquine Resistant Plasmodium Falciparum Malaria
- Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention
- Encephalitis due to Toxoplasmosis
- Malaria
- Toxoplasmosis
- Toxoplasmosis associated with acquired immunodeficiency syndrome
Off-label uses (2)
- Pneumocystis Carinii Pneumonia Prevention
- Toxoplasmosis Prevention
Contraindications (14)
- Acute nephropathy
- Anemia
- Anemia due to enzyme deficiency
- Bone marrow depression
- Deficiency of glucose-6-phosphate dehydrogenase
- Disease of liver
- Epilepsy
- Folic acid deficiency
- Kidney disease
- Megaloblastic anemia due to folate deficiency
- Neutropenic disorder
- Porphyria
- Third trimester pregnancy
- Thrombocytopenic disorder
Mechanism & targets
| Mechanism of action (MoA) | Dihydrofolate Reductase Inhibitors |
|---|---|
| Established pharmacologic class | Dihydrofolate Reductase Inhibitor Antimalarial |
Molecular targets (23)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | inhibitor | Ki 9.72 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | unknown | Ki 9.07 |
| Dihydrofolate reductase | dfrA17 | unknown | Ki 8.92 |
| Dihydrofolate reductase | folA | unknown | Ki 8.92 |
| Muscarinic acetylcholine receptor M1 | CHRM1 | unknown | Ki 8.72 |
| Dihydrofolate reductase | DHFR | unknown | Ki 8.10 |
| Dihydrofolate reductase | — | unknown | Ki 8.01 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | unknown | Ki 7.96 |
| Multidrug and toxin extrusion protein 1 | SLC47A1 | inhibitor | Ki 7.10 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | unknown | Ki 7.01 |
| Dihydrofolate reductase | DHFR | unknown | IC50 7.00 |
| Multidrug and toxin extrusion protein 1 | Slc47a1 | unknown | Ki 6.84 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | unknown | Ki 6.60 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | — | unknown | IC50 6.41 |
| Multidrug and toxin extrusion protein 2 | Slc47a2 | inhibitor | Ki 6.30 |
| Dihydrofolate reductase | Dhfr | unknown | IC50 5.85 |
| Beta-hexosaminidase subunit alpha | HEXA | unknown | IC50 5.51 |
| Solute carrier family 22 member 1 | Slc22a1 | unknown | Ki 5.44 |
| Beta-hexosaminidase subunit beta | HEXB | unknown | IC50 5.35 |
| Dihydrofolate reductase | DFR1 | unknown | IC50 5.30 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1953-01-23 | FDA | — | AMEDRA PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
P01BD01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Diaminopyrimidines |
P01BD51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Diaminopyrimidines |
P01BF04 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Artemisinin and derivatives, combinations |
P01BF09 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Artemisinin and derivatives, combinations |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Pancytopenia | 176.9 |
| Cerebral toxoplasmosis | 133.1 |
| Neutropenia | 97.3 |
| Drug reaction with eosinophilia and systemic symptoms | 89.6 |
| Urinary tract inflammation | 85.0 |
| Bone marrow failure | 77.1 |
| Hepatocellular injury | 63.3 |
| Pathogen resistance | 57.7 |
| Immune reconstitution inflammatory syndrome | 57.3 |
| Toxoplasmosis | 57.0 |
| Conductive deafness | 53.6 |
| Hepatitis cholestatic | 52.9 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Pyrimethamine is on its molecule page.
| Molecular formula | C12H13ClN4 |
|---|---|
| Molecular weight | 248.71 g/mol |
| CAS number | 58-14-0 |
| InChIKey | WKSAUQYGYAYLPV-UHFFFAOYSA-N |
| PubChem CID | 4993 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Pyrimethamine used for?
DrugCentral lists the following indications for Pyrimethamine: Chloroquine Resistant Plasmodium Falciparum Malaria, Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Encephalitis due to Toxoplasmosis, Malaria, Toxoplasmosis and Toxoplasmosis associated with acquired immunodeficiency syndrome.
How does Pyrimethamine work?
Pyrimethamine is classified as Dihydrofolate Reductase Inhibitors; its molecular targets in DrugCentral include Bifunctional dihydrofolate reductase-thymidylate synthase (inhibitor), Bifunctional dihydrofolate reductase-thymidylate synthase, dfrA17 and folA.
When was Pyrimethamine first approved?
Pyrimethamine was first approved by the FDA in 1953.
What drug class does Pyrimethamine belong to?
Pyrimethamine is in the Dihydrofolate Reductase Inhibitor Antimalarial class.
What is the chemical formula of Pyrimethamine?
Pyrimethamine has the molecular formula C12H13ClN4 and a molecular weight of 248.71 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2332 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL36 — compound record and bioactivity
- PubChem CID 4993 — chemical identifiers
- DrugBank DB00205 — drug record
- FDA UNII Z3614QOX8W — substance identity
- DailyMed: FDA labels for Pyrimethamine — current prescribing information (label search)
- UniProt P11229 (CHRM1) — target protein
- UniProt P00374 (DHFR) — target protein
- UniProt Q96FL8 (SLC47A1) — target protein
- UniProt P06865 (HEXA) — target protein
- UniProt P07686 (HEXB) — target protein
- UniProt O15245 (SLC22A1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.